Therapy Areas: Oncology
Arcus Biosciences' board announces grant of stock options at exercise price per share of USD37.56
12 January 2022 -

Oncology company Arcus Biosciences Inc (NYSE:RCUS) said on Tuesday that its board of directors' compensation committee awarded two new employees with stock options.

The two new employees received stock options to purchase a total of 41,800 shares of common stock from the company.

In addition, the new employees can exercise the common stock at an exercise price per share of USD37.56, which was the closing price on 10 January 2022.

These stock options were granted pursuant to the company's 2020 Inducement Plan, which was approved by the board of directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.



Related Headlines